Kivu Bioscience

Executive Summary

Kivu Bioscience is a San Diego-based clinical-stage biotechnology company advancing next-generation antibody-drug conjugates (ADCs) for oncology. Founded in 2018, the company leverages proprietary and licensed technologies to engineer ADCs with enhanced stability and potency, aiming to improve therapeutic efficacy while reducing off-target toxicity. Its pipeline targets solid tumors, with programs currently in preclinical and IND-enabling stages. The company is positioned to address key limitations of conventional ADCs through innovative linker and payload design. As a private entity with no disclosed funding or valuation, Kivu remains early-stage but holds potential for differentiation in the competitive ADC landscape. Its progress toward clinical validation will be critical for attracting partnerships and investment.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead ADC Program80% success
• Q2 2027Presentation of Preclinical Data at Major Oncology Conference90% success
• TBDStrategic Partnership or Licensing Agreement for Platform Technology30% success